{"id":"tp-56112","type":"article-newspaper","title":"BioStem Evaluates $10 Million to $12 Million in Annual Cash Cost Cuts","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/56112","datePublished":"2026-11-13T00:43:01.000Z","dateModified":"2026-11-13T00:43:01.000Z","language":"en","abstract":"Management expects operating expenses to decline and adjusted EBITDA losses to narrow in 2027. The planned manufacturing shift remains subject to validation and regulatory requirements.","section":"Business","references":[]}